ZyVersa Therapeutics, Inc. Announces Pricing of $11.0 Million Public Offering
April 26, 2023 09:10 ET
|
ZyVersa Therapeutics
WESTON, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...
ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson’s Disease
April 25, 2023 09:07 ET
|
ZyVersa Therapeutics
Parkinson’s disease (“PD”), the second leading cause of neurodegeneration in the world, is characterized by progressive degeneration of nigrostriatal dopaminergic neurons and intracellular...
ZyVersa Therapeutics Adds Dr. Douglas Golenbock to Its Inflammatory Disease Scientific Advisory Board to Support Advancement of Inflammasome ASC Inhibitor IC 100
April 24, 2023 09:07 ET
|
ZyVersa Therapeutics
Dr. Golenbock is The Neil and Margery Blacklow Chair in Infectious Diseases and Immunology and Professor and Chief, Division of Infectious Diseases and Immunology at the UMass Chan Medical...
ZyVersa Therapeutics Announces Article Published in Biomaterials Addressing the Critical Role of Inflammasome Activation in Neuroinflammation Resulting from Intracortical Implants
April 19, 2023 09:07 ET
|
ZyVersa Therapeutics
Deep brain stimulation devices are intracortical implants used to treat disabling symptoms of neurological conditions such as Parkinson's disease, epilepsy, essential tremor, and dystonia ...
ZyVersa Therapeutics Announces Review Article Published in Frontiers in Pharmacology Addressing Microglial Inflammatory Activity as a Pharmacological Target in Mild Cognitive Impairment and Alzheimer’s Disease
April 13, 2023 09:07 ET
|
ZyVersa Therapeutics
During aging, the central nervous system (“CNS”) becomes more inflammatory, leading to activation of microglia (“CNS immune cells”), tissue damage, dysfunction, and senescenceThe article reviews...
ZyVersa Therapeutics’ CEO, Stephen C. Glover to Appear on Benzinga 'All Access'
April 12, 2023 09:07 ET
|
ZyVersa Therapeutics
Mr. Glover will participate in a live interview on Benzinga All Access on April 18, 2023, to discuss the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200, for renal...
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Planet MicroCap Showcase
April 11, 2023 09:07 ET
|
ZyVersa Therapeutics
Mr. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease and Inflammasome ASC Inhibitor IC 100 for numerous CNS...
ZyVersa Therapeutics Announces Article Published in Brain Pathology Addressing Inflammasome Signaling Proteins in Alzheimer’s Disease
April 10, 2023 09:07 ET
|
ZyVersa Therapeutics
Increased inflammasome protein expression, NLRP1, NLRP3, ASC, and caspase-1, occurs early in Alzheimer’s disease (AD), indicating a role for multiple types of inflammasomes in disease development...
ZyVersa Therapeutics Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results
April 03, 2023 09:05 ET
|
ZyVersa Therapeutics
Key Highlights: Closed business combination with Larkspur Health Acquisition Corp. in December 2022 and began trading on Nasdaq Global Market under the ticker symbol “ZVSA”Planning underway with...
ZyVersa Therapeutics Reports New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2023 16:30 ET
|
ZyVersa Therapeutics
WESTON, Fla., March 13, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for...